Quick Overview
- Lutetium-177 PSMA therapy is available in Kenya.
- The treatment journey at HCG Cancer Centre is fully streamlined, coordinated, and multidisciplinary.
- Patients from across East Africa can access immediate premium care at HCG Cancer Centre without travelling abroad.
Why Advanced Prostate Cancer Treatment Matters in Kenya
Prostate cancer is one of the most commonly diagnosed cancers among men in Kenya and across sub-Saharan Africa. Unfortunately, many patients are diagnosed at advanced stages.
For years, patients across East Africa had to travel internationally to access certain advanced cancer treatments. That is now changing with HCG Cancer Centre at the forefront of bringing advanced oncology care to Kenya.
Read also: Lutetium-177: A Breakthrough in Advanced Prostate Cancer Treatment
What is Lutetium-177 PSMA Therapy
Lutetium-177 PSMA Therapy (Lu-177) is a targeted radioligand therapy that delivers radiation directly to prostate cancer cells. It works by attaching a radioactive molecule (Lutetium-177) to a carrier that specifically seeks PSMA on prostate cancer cells.
This is a major step forward from traditional chemotherapy, which affects the whole body.
Who Can Access Lutetium-177 Therapy at HCG Cancer Centre
Eligibility for Lutetium-177 therapy is based on a few key criteria:
- You have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC).
- Your cancer tests positive for PSMA, confirmed through a PSMA-PET scan.
- You have previously received androgen receptor pathway inhibitor (ARPI) hormone therapy.
- Your overall health and organ function support eligibility for this treatment.
Our oncology and nuclear team at HCG Cancer Centre will conduct a thorough clinical assessment and review your treatment history before confirming your eligibility.
What Does the Treatment Journey Look Like at HCG Cancer Centre
Step 1: Initial Oncology Consultation
You or your referring physician books a consultation with our oncology team. Bring all previous test results, scans, and treatment records, and our specialists will review your case and advise on the next steps.
Step 2: PSMA-PET Scan
If the initial assessment suggests potential eligibility, you will undergo a PSMA-PET Scan. This imaging test maps PSMA expression across your body and confirms whether you are a suitable candidate for Lutetium-177 treatment.
Step 3: Multidisciplinary Review
Your case is reviewed by our multidisciplinary team of nuclear medicine physicians, oncologists, and specialist nurses to design a personalised treatment plan.
Step 4: Treatment Cycles
Treatment is given as an IV infusion, and most patients do not need to be admitted overnight. Your response is monitored between cycles through PSA testing and imaging.
Step 5: Follow-Up and Long-Term Care
After treatment, our team continues to monitor your health, manage side effects, and assess your response to therapy, all within our comprehensive, integrated oncology care model.
What About Patients Travelling From Outside Kenya
HCG Cancer Centre regularly supports patients from Uganda, Tanzania, Rwanda, Ethiopia, and beyond the greater East and Sub-Saharan Africa. Our international patient support team can assist with appointment coordination, referral documentation, and guidance on accommodation in Nairobi.
Contact us directly to discuss how we can support your care journey.
